2018 / 06

Next Paper
DOI: 10.24075/brsmu.2018.089

ORIGINAL RESEARCH

Experimental study of dendrimer-based nanoparticles with RGD-peptide for anticancer radionuclide therapy

Stukalov YuV1, Grigorieva EYu1, Smirnova AV1,3, Lipengolts AA1,2, Kubasova IYu1, Pozdniakova NV1, Lukashina MI4
About authors

1 Blokhin National Medical Research Center of Oncology, Moscow

2 Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency, Moscow, Russia

3 The Loginov Moscow Clinical Scientific Center, Moscow, Russia

4 Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology, Moscow

Correspondеnce should be adressed: Elena Yu. Grigorieva
Kashirskoe shosse, 24, Moscow, 115478; ur.liam@11nele-girg

Received: 2018-09-12 Accepted: 2018-10-11 Published online: 2018-12-31
|
  1. Kulakov VN, Lipengolts AA, Grigorieva EYu, Shimanovskii NL. Pharmaceuticals for Binary Radiotherapy and Their Use for Treatment of Malignancies (A Review). Pharm Chem J. 2016 Sep 8; 50 (6): 388–93.
  2. Rakesh Kumar Tekade, Palanirajan Vijayaraj Kumar, Narendra Kumar Jain. Dendrimers in Oncology: An Expanding Horizon. Chem Rev. 2009; 109: 49–87.
  3. Wu L-R, Ficker M, Christensen JB. Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges. Bioconjugate Chem. 2015; 26: 1198–211.
  4. Olson ES, Jiang T, Aguilera T, Nguyen QT, Ellies LG, Scadeng M, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci. 2010; 107 (9): 4311–6.
  5. Palmerston Mendes L, Pan J, Torchilin V. Dendrimers as Nanocarriers for Nucleic Acid and Drug Delivery in Cancer Therapy. Molecules. 2017; 22 (9): 1401.
  6. Xu L, Yeudall WA, Yang H. Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery. Acta Biomater. 2017; (57): 251–61.
  7. Stukalov YuV, Grigorieva EYu, Kulakov VN, Baryshnikov AYu. Transport platform synthesis for drug development. Pharmaceutical chemistry journal. 2017; 51 (6): 480–1.
  8. Grigorieva EYu, Stukalov YV, Smirnova AV, Koldaeva EY, Kalygina NS, Kulakov VN et al. Cytotoxicity of Conjugates of 188Re-Labeled Dendrimers and Monoclonal Antibodies Anti- ICO-25 (MUC1) and Anti-ICO-80 (CD5) Against SKOV-3 (Ovary Cancer) and Jurkat Tumor Cell Lines (T-Lymphoblstic Lymphoma). Pharm Chem J. 2018; 52 (8): 681–4.
  9. Grigorieva EYu, Stukalov YuV, Koldaeva EYu. Konstruktsii na osnove dendrimerov novogo klassa dlya targetnoy radioterapii onkologicheskikh zabolevaniy. Rossiyskiy bioterapevticheskiy zhurnal. 2009; 8 (1): 5–6. Russian.
  10. Domingo-Espín J, Petegnief V, de Vera N. RGD-based cell ligands for cell-targeted drug delivery act as potent trophic factors. Nanomedicine: Nanotechnology, Biology, and Medicine. 2012; (8): 1263–6.
  11. Berman AE, Kozlova, NI, Morozevich GE. Integrins as a potential target for targeted anticancer therapy. Biochem. Moscow Suppl Ser B. 2012; 6 (3): 205–10.
  12. Miller LM, Pritchard JM, Macdonald SJF, Jamieson C, Watson AJB. The Emergence of Small Molecule Non-RGD-mimetic Inhibitors for RGD Integrins Journal of Medicinal Chemistry. 2017; 60 (8): 3241–51.
  13. Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol Oncol Clin North Am. 2004; 18 (5): 991–1006.
  14. Koistinen P, Ahonen M, Kähäri VM, Heino J. AlphaV integrin promotes in vitro and in vivo survival of cells in metastatic melanoma. Int J Cancer. 2004; 112 (1): 61–70.
  15. Kuphal S, Bauer R, Bosserhoff AK. Integrin signaling in malignant melanoma. Cancer Metastasis Rev. 2005; 24 (2): 195–222.
  16. Veeravagu A, Liu Z, Niu G, Chen K, Jia B, Cai W et al. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res. 2008; (14): 7330–9.
  17. Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY et al. Tumour-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia. 2008; 10 (11): 1259–67.
  18. Beiki D, Tajik M, Haddad P, Fallahi B, Arefpour AM, Mirzaei H et. al. Effectiveness and complications of 188Re-HEDP in palliative treatment of diffuse skeletal metastases. Iran J Nucl Med. 2015; 23 (1): 44–8.
  19. Erfani M, Doroudi A, Dinari MA, Shirmardi SP. Preparation of a rhenium-188 labeled bisphosphonate for bone pain palliation therapy. Journal of Radioanalytical and Nuclear Chemistry. 2015; 303 (3): 2027–32.
  20. Zamora PO, Gulhke S, Bender H. Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re- RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer. 1999; (6): 214–20.
  21. Molina-Trinidad EM, Arteaga de Murphy C, Ferro-Flores G. Radiopharmacokinetic and dosimetric parameters of 188Re-lanreotide in athymic mice with induced human cancer tumors. Int J Pharm. 2006; (310): 125–30.
  22. Krylov V, Kochetova T, Smolyarchuk M, Petriev V, Kanygin V, Alexandrova A et al. Evaluation of 188Re-khedp (phosphoren) for palliative treatment in patients with bone metastases., World Journal of Nuclear Medicine. 2013; 12 (2): 255–6.
  23. Kochetova T, Smolyarchuk M, Krylov V, Voloznev V, Lunev A, Petriev VM. 188Re-zoledronic acid: first in man study. World Journal of Nuclear Medicine. 2013; 12 (2): 228–9.
  24. Konior M, Iller E. Classic Radionuclide 188W/188Re Generator (Experiments, Design and Construction). Mod Chem appl. 2014; (2): 143.
  25. Evropejskaja konvencija po zashhite pozvonochnyh zhivotnyh, ispol'zuemyh dlja jeksperimental'nyh i drugih nauchnyh celej, EJeS, Strasburg, 1985 g. Lanimalogija. 1993; (1): 29 s.
  26. Belenkiy ML. Jelementy kolichestvennoj ocenki farmakologicheskogo jeffekta: L.: Izd-vo «MedGiz», 1968; 151 s.
  27. Guskova TA. Toksikologiya lekarstvennyh sredstv: M.: Izd-vo «Russkij vrach», 2003; 154 s.
  28. Trahtenberg IA, Sova AE, Sheftel VO, Onikienko FA. Problema normy v toksikologii. M.: Izd-vo «Medicina», 1992; 208 s.
  29. Seguin J, Nicolazzi C, Mignet N, Scherman D, Chabot GG. Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours. Tumour Biol. 2012; 33 (5): 1709–17.
  30. Treshhalina EM, Zhukova OS, Gerasimova GK, Andronova NV i dr. Metodicheskie rekomendacii po doklinicheskomu izucheniju protivoopuholevoj aktivnosti lekarstvennyh sredstv. V knige: Mironov AN, Bunatjan ND i dr., redaktory. Rukovodstvo po provedeniju doklinicheskih issledovanij lekarstvennyh sredstv. M.: Grif i K., 2012; S. 642–657.
  31. Koldaeva EYu, Grigorieva EYu, Stukalov YuV. Sravnitel'naja toksikologija nanokonstrukcij na osnove dendrimerov dlja targetnoj radioterapii v onkologii. Rossijskij Bioterapevticheskij Zhurnal. 2010; 9 (3): 13–14.
  32. Argyrou M, Valassi A, Andreou M, Lyra M. Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy. Int J Mol Imaging. 2013; (2013): 1–7.